Myocardial infarction type 1 is frequent in refractory out-of-hospital cardiac arrest (OHCA) treated with extracorporeal cardiopulmonary resuscitation (ECPR)

D. Duerschmied1,2✉, V. Zotzmann1,2, M. Rieder1,2, X. Bemtgen1,2, P. M. Biever1,2, K. Kaier3, G. Trummer4, C. Benk4, H. J. Busch5, C. Bode5,2, T. Wengenmayer1,2, P. Stachon5,2, C. von zur Mühlen1,2 & D. L. Staudacher1,2

Extracorporeal cardiopulmonary resuscitation (ECPR) is a last resort treatment option for refractory cardiac arrest performed in specialized centers. Following consensus recommendations, ECPR is mostly offered to younger patients with witnessed collapse but without return of spontaneous circulation (ROSC). We report findings from a large single-center registry with 252 all-comers who received ECPR from 2011–2019. It took a median of 52 min to establish stable circulation by ECPR. Eighty-five percent of 112 patients with out-of-hospital cardiac arrest (OHCA) underwent coronary angiography, revealing myocardial infarction (MI) type 1 with atherothrombotic vessel obstruction in 70 patients (63% of all OHCA patients, 74% of OHCA patients undergoing coronary angiography). Sixty-six percent of 140 patients with intra-hospital cardiac arrest (IHCA) underwent coronary angiography, which showed MI type 1 in 77 patients (55% of all IHCA patients, 83% of IHCA patients undergoing coronary angiography). These results suggest that MI type 1 is a frequent finding and - most likely - cause of cardiac arrest (CA) in patients without ROSC, especially in OHCA. Hospital survival rates were 30% and 29% in patients with OHCA and IHCA, respectively. According to these findings, rapid coronary angiography may be advisable in patients with OHCA receiving ECPR without obvious non-cardiac cause of arrest, irrespective of electrocardiogram analysis. Almost every third patient treated with ECPR survived to hospital discharge, supporting previous data suggesting that ECPR may be beneficial in CA without ROSC. In conclusion, interventional cardiology is of paramount importance for ECPR programs.

Current treatment algorithms for cardiac arrest (CA) advocate a prompt treatment of the underlying cause1. In patients with ST-segment elevation myocardial infarction (STEMI), revealed by 12-lead electrocardiogram analysis after return of spontaneous circulation (ROSC), an immediate coronary angiography with percutaneous coronary intervention (PCI) improves outcome2. Registry data on out-of-hospital cardiac arrest (OHCA) suggest a coronary cause of CA in 29% to 43% of patients presenting without ST-segment elevation3,4. OHCA patients without STEMI might therefore also benefit from an early coronary angiography.

1Department of Medicine III (Interdisciplinary Medical Intensive Care), Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany. 2Department of Cardiology and Angiology I, Heart Center, University of Freiburg, Freiburg, Germany. 3Institute for Medical Biometry and Statistics, Faculty of Medicine, University of Freiburg, Freiburg, Germany. 4Department of Cardiovascular Surgery, Heart Center Freiburg University, University of Freiburg, Freiburg, Germany. 5Department of Emergency Medicine, University Hospital of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany. ✉e-mail: daniel.duerschmied@universitaets-herrzentr.de
However, more information about patients receiving extracorporeal cardiopulmonary resuscitation (ECPR) is needed, because this is a selected patient cohort. In refractory CA, ECPR is considered an ultima ratio treatment option if ROSC cannot be achieved within 30 min of conventional CPR. According to consensus recommendations, ECPR should be considered in case of refractory CA if favorable prognostic factors are present and unfavorable factors are absent. Figure 1 shows the decision algorithm used in our center to determine a possible indication or contra-indication for initiating ECPR. Notably, patients of advanced age (≥75 years old) will not routinely receive ECPR. A no-flow time of >8 min, an unwitnessed collapse, and an evident untreatable cause of CA are other factors that would not prompt ECPR initiation, but rather lead to termination of resuscitation efforts. Favorable factors are signs of life under CPR, an initially shockable rhythm, and sufficient end-tidal CO2. Decision-making pro or contra initiation of ECPR is recommended after 15 min of advanced life support in our and many other centers to minimize low-flow time.

Together, these criteria are meant to ensure that a resource-intensive and highly invasive procedure such as ECPR is reserved to CA patients without ROSC, but still rather favorable prognosis. ECPR patients are therefore a very distinct patient cohort, defined by criteria that also favor the selection of patients with a treatable, most often cardiac cause of CA. Therefore, we set out to further investigate logistics and outcome of ECPR patients using an all-comers single-center registry.

**Methods**

**Study setting.** Presented data derive from a single-center retrospective registry analysis with ethics approval (Ethics Committee of Albert-Ludwigs University of Freiburg, file number 151/14 and 533/19). Only anonymized clinical data were obtained retrospectively from a cardiac arrest cohort with many non-survivors and the ethics committee waived the need for individual written informed consent. All methods were performed in accordance with relevant guidelines and regulations. This study includes all patients receiving ECPR at our tertiary referral university hospital between May 2011 and May 2019. ECPR was defined as VA-ECMO implantation during continuous CPR without ROSC or as VA-ECMO implantation within the first 20 min after ROSC with uncontrollable hemodynamic instability. All VA-ECMO cases treated at our institution were detected by a computerized search for the German OPS-codes (Operationen- und Prozedurenschlüssel) for VA-ECMO (8–852.30–8–852.30e), followed by manual review on case-by-case basis. All patients treated at the interdisciplinary medical intensive care unit were considered for this retrospective registry analysis, excluding patients cannulated for VA-ECMO in the operation theatre and treated at a surgical intensive care unit.

**Local ECPR algorithm.** Since 2011, all patients with IHCA without ROSC after 15 minutes are routinely screened for an indication for ECPR. As defined by our standard operating procedures, unwitnessed cardiac arrest, prolonged duration of CPR without signs of life (breathing, swallowing etc.), a non-shockable initial rhythm, life-threatening bleeding and advanced age ≥75 years are considered relative contraindications for
ECMO cannulation (Fig. 1). Final decision to cannulate is driven by a team decision at the bedside including at least two physicians, a perfusionist, and two nurses. Local standard operating procedure suggests cannulation for ECPR after IHCA on-site or in the cardiac catheterization laboratory, whichever results in shorter low-flow durations. For OHCA, emergency medical services personnel are encouraged to transport patients without ROSC with ongoing mechanical chest compressions to our center, where the patients are screened for ECPR. The same contraindications apply as for IHCA patients. OHCA patients were either routed to the emergency room or the cardiac catheterization laboratory, according to the presumed cause for collapse, non-cardiac or cardiac, respectively11. Screening for ECPR and cannulation were then performed in the emergency room or the catheterization laboratory, whichever destination had been chosen. Starting in August 2018, an out-of-hospital ECPR service was implemented, offering on-site out-of-hospital ECPR during working hours (10 patients in this cohort).

**ECMO cannulation and maintenance.** Local standard operating procedures suggest cannulation for ECPR to be performed in Seldinger’s technique by two experienced intensivists and one perfusionist. SCPC (Sorin Centrifugal Pump Console, LivaNova, London, United Kingdom) or Cardiohelp (Maquet Getinge Group, Rastatt, Germany) systems could be used. Typical venous (draining) cannulas were 21–23 Fr (French = Charrière) in diameter and 55 cm of length while arterial (returning) cannulas were 15–17 Fr, 23 cm (both HLS cannula, Maquet Getinge Group, Rastatt, Germany). For patients without life-threatening bleeding, anticoagulation was provided by intravenous administration of unfractionated heparin aiming at a partial thromboplastin time of 50–60 sec. The management of vasopressors and fluid therapy was driven by clinical judgement of the ECMO-experienced intensivist in charge and has been reported earlier12,33. Notably, more liberal fluid resuscitation with albumin (in a 1:2 ratio with balanced crystalloid solution) was introduced in 2016.

**Coronary angiography after ECPR.** Early detection and treatment of the cause for collapse was attempted in all ECPR cases. A coronary angiography was therefore performed in all patients with a presumed cardiac cause. In case of presumed non-cardiac cause and non-conclusive findings in ultrasound and computed tomography studies, a coronary angiography is advertised by local standard operating procedures. Intervention of a coronary stenosis detected by angiography was performed if recommended by current guidelines14. Types of MI were primarily diagnosed by the responsible interventionalist, but then adjudicated by an experience, independent cardiologist off-line15. MI Type 1 was adjudicated in patients with myocardial necrosis (defined by troponin T above the 99th percentile upper reference limit) if a total or sub-total atherothrombotic vessel obstruction was present and treated by PCI. MI Type 2 was adjudicated in patients with myocardial necrosis if a hemodynamically relevant coronary artery stenosis ≥75% without total or sub-total vessel obstruction was present and treated by PCI. All other cases of CA were allocated to a non-MI cause of arrest.

**Data analysis.** For data analysis, Prism (version 7, GraphPad) was used and a p-value of <0.05 was considered statistically significant. All data are given as [mean ± standard deviation] if not stated otherwise. Unpaired t test (if Gaussian distribution was assumed as tested by Kolmogorov-Smirnov normality test) or Mann-Whitney test (in cases where normal distribution could not be assumed) were used to compare values from OHCA versus IHCA patients. Normal distribution was assumed for the parameters SAPS II, pH, lactate, hemoglobin, K⁺, contrast agent volume, and number of vessels treated. Fisher’s exact test was used to interpret contingency tables.

**Results**

**Patient characteristics.** Out of 273 all-comer cases receiving ECPR during the observational period, 252 complete data sets could be retrieved from the registry (Fig. 2). Patients receiving ECPR for OHCA were significantly younger than patients receiving ECPR for IHCA, with an overall mean age of 59 years (Table 1). Other baseline characteristics were equally distributed between the OHCA and IHCA groups, but underlying lung disease, hypertension, diabetes mellitus, chronic kidney disease, and dyslipidemia were more frequent in IHCA patients.

Patients presented with a shockable rhythm in 59% and 38% in OHCA and IHCA, respectively. While the median no-flow time was <1 min, we observed a wide range from 0 up to 30 min (in one OHCA patient who did not survive to hospital discharge). No-flow time was significantly longer in OHCA than in IHCA. The median time from collapse to start of ECMO, i.e. established extracorporeal circulation, was 64 min in OHCA and 45 min in IHCA patients.

Initial – first measured – pH was 7.1 in OHCA and 7.2 in IHCA. As expected from a patient cohort with refractory CA, initial lactate levels were relatively high with a mean of 11.8 mmol/L in OHCA and 10.5 mmol/L in IHCA. Also, reflecting the severity of disease, initial SAPS II was high in both groups.

**Patient survival.** Mean duration of VA-ECMO was 131 h, without significant differences between OHCA and IHCA patients. Mean ECMO flow rate in the entire cohort was 3.6 l/min after 24 h. Twenty-nine percent of all patients survived to hospital discharge – without significant differences between the groups.

**Coronary angiography findings.** In total, a coronary angiography was performed in 75% of cases, with a higher frequency in OHCA (85%, Fig. 2) than in IHCA (66%). Most likely, this can be explained by other causes of CA that were suspected, diagnosed, and promptly treated in patients with IHCA as compared to OHCA. For instance, relevant lung disease was more than twice as frequent in IHCA than in OHCA patients. IHCA patients were also older and presented with other comorbidities, including chronic kidney disease (Table 1) and initially increased markers of renal dysfunction (first values of blood urea nitrogen and creatinine measured after ECPR were significantly higher in IHCA patients, Table 2).

MI Type 1 was diagnosed in 63% of OHCA patients and 55% of IHCA patients, a difference that was not statistically significant (Table 3, Fig. 2). Non-occluded, but severely stenosed coronary arteries were diagnosed in
less than 5% of all cases (classified as MI Type 2), without a significant difference between the groups. As expected in a CA patient cohort, door-to-balloon time was relatively long (46 min). Surprisingly, IHCA patients had a significantly longer door-to-balloon time (53 min) than OHCA patients (39 min). The most likely reason for this difference was the significantly higher rate of shockable rhythm in OHCA patients, indicating a cardiac cause of arrest and prompting more rapid coronary angiography and PCI. In IHCA, other causes of CA were often suspected and differential diagnostic procedures performed first.

The survival rate of patients with MI Type 1 was similar to the entire cohort. Survival rates of the groups of patients with MI Type 2 (17%) or other cause of CA (26%) were smaller than the survival rate of patients with MI Type 1 (29%), but these differences were not statistically significant (p = 0.513 and p = 0.851, respectively). When interpreting these numbers, the smaller sizes of the groups of patients with MI Type 2 (n = 12) of other cause of CA (n = 83) as compared to the group of patients with MI Type 1 (n = 147) should be considered.

Kidney injury. We observed acute kidney injury in approximately 64% of all patients and saw no significant difference between OHCA and IHCA patients. Hemodialysis was performed in 23% of all patients (no significant difference between the groups).

The equal frequencies of kidney injury and hemodialysis did not reflect the significantly larger volume of contrast agent used in IHCA patients. Following IHCA, not only was more contrast agent used, but also more vessels were treated and more stents were implanted (both not significant). Notably, significantly more left main stem PCIs were performed in IHCA patients (29%) as compared to OHCA (16%). These results are in line with the observation that IHCA occurred peri-interventionally during especially complex and/or complicated PCIs in 24%. Out of peri-interventional IHCA cases, 47% required left main PCIs. Therefore, PCI was more complicated in our IHCA cohort, because complex PCI was the cause of IHCA in many cases, but this did not translate into a higher rate of acute kidney injury.

Discussion

Immediate coronary angiography after ECPR. Whether early coronary angiography should be performed in all ECPR patients, or only after selection according to interpretation of electrocardiogram and other information as recommended in patients without CA or after ROSC, has not been investigated systematically. For patients with refractory CA without ROSC, current guidelines recommend an urgent coronary angiography only if it appears logistically feasible and if an acute coronary syndrome is suspected. Shockable primary rhythm is associated with both cardiac cause for collapse and improved outcome in ECPR and is consequently one of the factors in favor of ECPR initiation. In addition, logistics in a catheterization laboratory appear ideal for
in the mobile intensive care unit had relevant coronary artery disease. This is in line with earlier data from Table 1.

Baseline characteristics. BMI – Body mass index; *Lung disease: history of COPD, asthma, lung fibrosis, cystic fibrosis; CAD - history of coronary artery disease; PAD - history of peripheral arterial disease; SAPS - Simplified acute physiology score, bold p values denote statistically significant differences.

|                               | All (n = 252) | OHCA (n = 112) | IHCA (n = 140) | p OHCA vs. IHCA |
|-------------------------------|--------------|--------------|--------------|----------------|
| Age (y)                       | 59.0 ± 14.3  | 54.8 ± 14.3  | 62.5 ± 13.5  | <0.0001        |
| Male                          | 186 (73.8%)  | 88 (78.6%)   | 98 (70.0%)   | 0.1496         |
| BMI (kg/m²)                   | 27.0 ± 5.1   | 26.7 ± 4.7   | 27.2 ± 5.3   | 0.5837         |
| Lung disease†                 | 35 (13.9%)   | 9 (8%)       | 26 (18.6%)   | 0.0175         |
| Hypertension                  | 98 (38.9%)   | 31 (27.7%)   | 67 (47.9%)   | 0.0012         |
| Diabetes mellitus             | 58 (23.0%)   | 12 (10.7%)   | 46 (32.9%)   | <0.0001        |
| CAD                           | 148 (58.7%)  | 59 (52.7%)   | 89 (63.6%)   | 0.0945         |
| PAD                           | 17 (6.7%)    | 6 (5.4%)     | 11 (7.9%)    | 0.4624         |
| Chronic kidney disease        | 42 (16.7%)   | 10 (8.9%)    | 32 (22.9%)   | 0.0036         |
| Dyslipidemia                  | 56 (22.2%)   | 18 (16.1%)   | 38 (27.1%)   | 0.0470         |
| Smoking                       | 68 (27.0%)   | 24 (21.4%)   | 44 (31.4%)   | 0.0872         |
| Shockable rhythm              | 120 (47.6%)  | 66 (58.9%)   | 54 (38.6%)   | 0.0015         |
| No-flow time (minutes/median; mean ± SD) | 0 (0–30); 1.8 ± 0.2 | 0 (0–30); 3.5 ± 6.6 | 0 (0–15); 6.0 ± 2.2 | <0.0001 |
| Time to ECMO (minutes/median; mean ± SD) | 52 (10–150); 56.2 ± 28.0 | 64 (15–150); 67.4 ± 29.0 | 45 (10–140); 47.3 ± 23.8 | <0.0001 |
| Initial pH                    | 7.15 ± 0.2   | 7.07 ± 0.2   | 7.21 ± 0.2   | <0.0001        |
| Initial pCO₂ (mmHg)           | 49.4 ± 23.4  | 52.6 ± 23.0  | 47.2 ± 23.6  | 0.1144         |
| Initial pO₂ (mmHg)            | 20.6 ± 95.5  | 91.1 ± 85.3  | 123.8 ± 101.2 | 0.1059 |
| Initial lactate (mmol/L)      | 11.0 ± 8.6   | 11.8 ± 4.9   | 10.5 ± 10.5  | 0.2972         |
| Initial hemoglobin (g/dL)     | 12.0 ± 3.3   | 13.2 ± 2.6   | 10.9 ± 3.5   | 0.0035         |
| Initial K⁺ (mmol/L)           | 4.7 ± 1.2    | 4.8 ± 1.3    | 4.6 ± 1.0    | 0.3730         |
| Initial SAPS II               | 79.4 ± 12.5  | 78.8 ± 11.4  | 79.8 ± 13.3  | 0.5221         |

Table 1. Baseline characteristics. BMI – Body mass index; *Lung disease: history of COPD, asthma, lung fibrosis, cystic fibrosis; CAD - history of coronary artery disease; PAD - history of peripheral arterial disease; SAPS - Simplified acute physiology score, bold p values denote statistically significant differences.

|                               | All (n = 252) | OHCA (n = 112) | IHCA (n = 140) | p OHCA vs. IHCA |
|-------------------------------|--------------|--------------|--------------|----------------|
| VA-ECMO duration (h)          | 130.7 ± 587.8 | 151.6 ± 835.4 | 114.1 ± 263.0 | 0.6176         |
| Hospital Survival             | 74 (29.4%)   | 33 (29.5%)   | 41 (29.3%)   | >0.9999        |
| First blood urea nitrogen after ECPR (mg/dL) | 52.8 ± 34.6 | 42.1 ± 24.8 | 62.2 ± 39.1 | <0.0001 |
| First creatinine after ECPR (mg/dL) | 1.6 ± 1.2 | 1.4 ± 0.8 | 1.8 ± 1.4 | 0.0107 |
| Acute kidney injury           | 160 (63.5%)  | 69 (61.6%)   | 91 (65.0%)   | 0.6004         |
| Hemodialysis                  | 58 (23.0%)   | 22 (19.6%)   | 36 (25.7%)   | 0.2931         |

Table 2. Outcome data. Bold p values denote statistically significant differences.

rapid, sterile, effective, and safe cannulation to establish VA-ECMO under CPR. It is therefore conceivable that in-hospital ECPR in a cardiac catheterization laboratory followed by immediate coronary angiography may be beneficial.

An analysis of the Paris registry recently showed that 73% of OHCA patients receiving pre-hospital ECPR in the mobile intensive care unit had relevant coronary artery disease. This is in line with earlier data from the French PROCAT II-registry showing that among patients with ROSC after OHCA and without ST-segment elevation, 29% were treated with PCI. PCI was associated with better outcome in these patients. Much higher rates of severe coronary artery disease were found in patients with refractory ventricular fibrillation (up to 84%) in a US registry. Our analysis is the first to examine the rates of MI Types 1 and 2 in ECPR patients after OHCA and IHCA.

The results from the all-comers cohort of ECPR patients treated at our center support the earlier data: Sixty-three percent of all OHCA patients had an MI Type 1 and another 4% had an MI Type 2. This means that two thirds of OHCA patients had severe and ongoing myocardial necrosis, which should be stopped as soon as possible by revascularization to prevent further myocardial scarring according to all current guidelines.

We conclude that immediate coronary angiography should be offered to all ECPR patients without obvious non-cardiac cause of CA. Ideally, CA patients without ROSC and scheduled for ECPR should therefore be transferred into a cardiac catheterization laboratory, where VA-ECMO can be implanted first and coronary angiography can be performed immediately after that. Further diagnostic workup, including whole-body computed imaging, would then be performed parallelly.
yet increased shortly after CPR, a mean SAPS II of 79 (Table 1) predicts a disastrous hospital survival rate of the severity of disease in CA patients, because parameters such as blood urea nitrogen or bilirubin have not long-term outcome.

data as being clearly in favor of ECPR, which we believe not only saves lives, but lives with favorable neurological (14.5 mmol/L) in ECPR patients compared to patients treated with conventional CPR (6.9 mmol/L). The French vival close to 0%. Further illustrating this imbalance between study groups was a more than doubled lactate level that ECPR was predominantly provided to patients not achieving ROSC – a patient cohort with an expected sur- interesting ECPR compared to 77% of patients receiving conventional CPR in this report. This supports the assumption values denote statistically significant differences.

MI Type 1 – atherothrombotic vessel occlusion; MI Type 2 – MI not caused by atherothrombotic vessel occlusion, but a coronary artery stenosis ≥75%, bold p values denote statistically significant differences.

| Parameter                                      | All (n = 252) | OHCA (n = 112) | IHCA (n = 140) | p OHCA vs. IHCA |
|------------------------------------------------|---------------|---------------|---------------|----------------|
| Coronary angiography performed within 24h      | 188 (74.6%)   | 95 (84.8%)    | 93 (66.4%)    | 0.0008         |
| ECMO to coronary angiography time (h)         | 0.6 ± 1.74    | 0.5 ± 0.8     | 0.7 ± 2.4     | 0.4112         |
| Contrast agent volume (mL)                    | 295.2 ± 178.5 | 236.6 ± 125.6 | 353.8 ± 203.4 | <0.0001        |
| MI Type 1 treated with PCI                    | 147 (58.3%)   | 70 (62.5%)    | 77 (55.0%)    | 0.2489         |
| MI Type 2 treated with PCI                    | 12 (4.8%)     | 4 (3.6%)      | 8 (5.7%)      | 0.5565         |
| Cause of cardiac arrest other than MI         | 93 (36.9%)    | 38 (34.0%)    | 55 (39.3%)    | 0.4312         |
| Vessels treated (number)                      | 1.5 ± 0.7     | 1.4 ± 0.6     | 1.6 ± 0.7     | 0.925          |
| Left main PCI                                 | 48 (23.8%)    | 18 (16.1%)    | 30 (29.4%)    | 0.0221         |
| Stents implanted (number)                     | 2.2 ± 2.1     | 1.9 ± 1.8     | 2.5 ± 2.3     | 0.780          |
| Door-to-balloon time (min)                    | 46.0 ± 26.6   | 39.1 ± 18.5   | 52.6 ± 31.4   | 0.0024         |

| Cause of cardiac arrest other than MI         | 93 (36.9%)    | 38 (34.0%)    | 55 (39.3%)    | 0.4312         |
| Vessels treated (number)                      | 1.5 ± 0.7     | 1.4 ± 0.6     | 1.6 ± 0.7     | 0.925          |
| Left main PCI                                 | 48 (23.8%)    | 18 (16.1%)    | 30 (29.4%)    | 0.0221         |
| Stents implanted (number)                     | 2.2 ± 2.1     | 1.9 ± 1.8     | 2.5 ± 2.3     | 0.780          |
| Door-to-balloon time (min)                    | 46.0 ± 26.6   | 39.1 ± 18.5   | 52.6 ± 31.4   | 0.0024         |

Table 3. Coronary angiography results. MI – myocardial infarction; PCI – percutaneous coronary intervention; MI Type 1 – atherothrombotic vessel occlusion; MI Type 2 – MI not caused by atherothrombotic vessel occlusion, but a coronary artery stenosis ≥75%, bold p values denote statistically significant differences.

...tomography, can then be integrated into the post-CA care algorithm (Fig. 1), ideally very early, i.e. directly after coronary angiography21. In our center, echocardiography is routinely performed much earlier: during advanced life support in the pre-hospital setting or together with endotracheal tube position control and blood gas analysis as first steps in the cardiac catheterization laboratory as part of a focused abdominal sonography for trauma and focused echocardiography in emergency life support algorithm6,11–13,22.

Survival. Although the initial prognostication for survival by scores such as SAPS II will underestimate the severity of disease in CA patients, because parameters such as blood urea nitrogen or bilirubin have not yet increased shortly after CPR23, a mean SAPS II of 79 (Table 1) predicts a disastrous hospital survival rate of <10%24,25. In contrast to this poor prognosis, we observed a much higher survival rate in our ECPR patients of 29%, suggesting that ECPR improved survival. Our registry data are however not suitable to provide high-level evidence supporting this statement and a randomized controlled trial is desirable to determine whether ECPR saves lives.

A recent controversy about this question increased the need for such high level of evidence-providing trials, one of which is currently recruiting patients (ClinicalTrials.gov Identifier: NCT03637205). Rather disappointing results from a large French registry showed similar hospital survival rates of 8% in CA both with and without ECPR26. It should be noted, however, that the duration of CPR was longer than 30 min in 99% of patients receiving ECPR compared to 77% of patients receiving conventional CPR in this report. This supports the assumption that ECPR was predominantly provided to patients not achieving ROSC – a patient cohort with an expected survival close to 0%. Further illustrating this imbalance between study groups was a more than doubled lactate level (14.5 mmol/L) in ECPR patients compared to patients treated with conventional CPR (6.9 mmol/L). The French study hence contained a relevant bias and should not be interpreted as showing a null effect of ECPR, but rather inform about factors that need to be improved to increase survival, such as patient selection.

Evidence in favor of ECPR was reported from the Brussels group with an improved favorable neurological outcome at 3 months (defined as cerebral performance category 1–2) of 21% in CA patients receiving ECPR as compared to 11% in patients receiving conventional CPR27. Hospital survival was 23% in ECPR patients compared to 18% with conventional CPR. Hospital survival was even higher in our cohort (29%). We recently reported surprisingly good emotional and physical functioning in long-term ECPR survivors (beyond 2 years), which was comparable to the general 55–64 years-old Dutch population28. Taken together, we interpret these data as being clearly in favor of ECPR, which we believe not only saves lives, but lives with favorable neurological long-term outcome.

Limitations. This is a retrospective observational study and therefore contains the risk of selection and reporting bias. Moreover, this is a single-center report and specific processes may influence the presented results.

Conclusion Two-thirds of patients with refractory OHCA receiving ECPR had MI Type 1 or 2 warranting immediate revascularization to salvage viable myocardium. Thirty percent of OHCA patients survived to hospital discharge. Considering that ECPR long-term survivors have a favorable neurological outcome, minimizing myocardial scarring and preventing subsequent heart failure appears of paramount importance. We therefore suggest that coronary angiography should be performed in ECPR patients without obvious non-cardiac cause of CA as soon as possible. Ideally, we propose that in-hospital ECPR be performed inside a cardiac catheterization laboratory,
followed by coronary angiography. Out-of-hospital ECPR patients should be transferred directly to a catheterization laboratory.

Received: 13 February 2020; Accepted: 5 May 2020;
Published online: 21 May 2020

References
1. Soar, J. et al. European Resuscitation Council Guidelines for Resuscitation 2015: Section 3. Adult advanced life support. Resuscitation 95, 100–147, https://doi.org/10.1016/j.resuscitation.2015.07.016 (2015).
2. Scholz, K. H. et al. Impact of treatment delay on mortality in ST-segment elevation myocardial infarction (STEMI) patients presenting with and without haemodynamic instability: results from the German prospective, multicentre FITT-STEMI trial. Eur Heart J 39, 1065–1074, https://doi.org/10.1093/eurheartj/ehy004 (2018).
3. Dumas, F. et al. Emergency Percutaneous Coronary Intervention in Post-Cardiac Arrest Patients Without ST-Segment Elevation Pattern: Insights From the PROCAT II Registry. JACC Cardiovasc Interv 9, 1011–1018, https://doi.org/10.1016/j.jcin.2016.02.001 (2016).
4. Dumas, F. et al. Immediate percutaneous coronary intervention is associated with better survival after out-of-hospital cardiac arrest: insights from the PROCAT (Parisian Region Out of hospital Cardiac Arrest) registry. Circ Cardiovasc Interv 3, 200–207, https://doi.org/10.1161/CIRCINTERVENTIONS.109.913665 (2010).
5. Wengenmayer, T. & Staudacher, D. L. Need for speed in out-of-hospital cardiac arrest. Resuscitation 144, 187–188, https://doi.org/10.1016/j.resuscitation.2019.08.033 (2019).
6. Michels, G. et al. Recommendations for extracorporeal cardiopulmonary resuscitation (eCPR): consensus statement of DGIIN, DGK, DGTHG, DGNI, DGAII, DJVI and GRC. Clin Res Cardiol, https://doi.org/10.1007/s00392-018-1366-4 (2018).
7. Abrams, D. et al. Position paper for the organization of ECMO programs for cardiac failure in adults. Intensive Care Med 44, 717–729, https://doi.org/10.1007/s00134-018-5064-5 (2018).
8. Lamhaut, L. et al. A Pre-Hospital Extracorporeal Cardio Pulmonary Resuscitation (eCPR) strategy for treatment of refractory out hospital cardiac arrest: An observational study and propensity analysis. Resuscitation 117, 109–117, https://doi.org/10.1016/j.resuscitation.2017.04.014 (2017).
9. Wengenmayer, T. et al. Influence of low-flow time on survival after extracorporeal cardiopulmonary resuscitation (eCPR). Crit Care 21, 157, https://doi.org/10.1186/s13054-017-1744-8 (2017).
10. Jacobs, I. et al. Cardiac arrest and cardiopulmonary resuscitation outcome reports: update and simplification of the Utstein templates for resuscitation registries: a statement for healthcare professionals from a task force of the International Liaison Committee on Resuscitation (American Heart Association, European Resuscitation Council, Australian Resuscitation Council, New Zealand Resuscitation Council, Heart and Stroke Foundation of Canada, InterAmerican Heart Foundation, Resuscitation Councils of Southern Africa). Circulation 110, 3385–3397, https://doi.org/10.1161/CIRC0000147236.85306.15 (2004).
11. Busch, H. J. et al. [Freiburg Cardiac Arrest Receiving Team (CART): Interdisciplinary solution for the acute management of non-traumatic out-of-hospital cardiac arrest]. Med Klin Intensivmed Notfmed 94, 7–11, https://doi.org/10.1007/s00134-019-0598-8 (2019).
12. Staudacher, D. L., Gold, W., Biever, P. M., Bode, C. & Wengenmayer, T. Early fluid resuscitation and volume therapy in venaoteral extracorporeal membrane oxygenation. J Crit Care 37, 130–135, https://doi.org/10.1016/j.jcrc.2016.09.017 (2017).
13. Wengenmayer, T. et al. Albumin fluid resuscitation in patients on venaoteral extracorporeal membrane oxygenation (VA-ECMO) therapy is associated with improved survival. Intensive Care Med 44, 2312–2314, https://doi.org/10.1007/s00134-018-5443-y (2018).
14. Neumann, F. J. et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J, https://doi.org/10.1093/eurheartj/ehy394 (2018).
15. Thygesen, K. et al. Fourth Universal Definition of Myocardial Infarction (2018). J Am Coll Cardiol 72, 2231–2264, https://doi.org/10.1016/j.jacc.2018.08.1038 (2018).
16. Park, J. et al. Clinical Factors Associated with Obstructive Coronary Artery Disease in Patients with Out-of-Hospital Cardiac Arrest: Data from the Korean Cardiac Arrest Research Consortium (KoCARC) Registry. J Korean Med Sci 34, e159, https://doi.org/10.3346/jkms.2019.34.e159 (2019).
17. Wang, J., Ma, Q., Zhang, H., Liu, S. & Zheng, Y. Predictors of survival and neurologic outcome for adults with extracorporeal cardiopulmonary resuscitation: A systemic review and meta-analysis. Medicine (Baltimore) 97, e13257, https://doi.org/10.1097/MD.0000000000013257 (2018).
18. Ternus, B. et al. Initiation of Extracorporeal Membrane Oxygenation in the Cardiac Catheterization Laboratory: The Mayo Clinic Experience. J Invasive Cardiol (2019).
19. Lamhaut, L. et al. Coronary lesions in refractory out of hospital cardiac arrest (OHCA) treated by extra coronary pulmonary resuscitation (ECPR). Resuscitation 126, 154–159, https://doi.org/10.1016/j.resuscitation.2017.12.017 (2018).
20. Yannopoulos, D. et al. Coronary Artery Disease in Patients With Out-of-Hospital Refractory Ventricular Fibrillation Cardiac Arrest. J Am Coll Cardiol 70, 1109–1117, https://doi.org/10.1016/j.jacc.2017.06.059 (2017).
21. Zottmann, V. et al. Early full-body computed tomography in patients after extracorporeal cardiopulmonary resuscitation (eCPR). Resuscitation 146, 149–154, https://doi.org/10.1016/j.resuscitation.2019.11.024 (2020).
22. Zottmann, V. et al. Epinephrine, inodilator, or no inotrope in venaoteral extracorporeal membrane oxygenation implantation: a single-center experience. Crit Care 23, 320, https://doi.org/10.1186/s13054-019-2665-4 (2019).
23. Wengenmayer, T. et al. Development and validation of a prognostic model for survival in patients treated with venaoteral extracorporeal membrane oxygenation: the PREDICT VA-ECMO score. Eur Heart J Acute Cardiac Care 8, 359–359, https://doi.org/10.1177/204887651879052 (2019).
24. Godinak, J. et al. Predictive value of SAPS II and APACHE II scoring systems for patient outcome in a medical intensive care unit. Acta Med Acad 45, 97–103, https://doi.org/10.1556/ama2006-124.165 (2016).
25. Le Gall, J. R., Lemeshow, S. & Saulnier, F. A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. JAMA 270, 2957–2963, https://doi.org/10.1001/jama.270.24.2957 (1993).
26. Bougouin, W. et al. Extracorporeal cardiopulmonary resuscitation in out-of-hospital cardiac arrest: a registry study. Eur Heart J, https://doi.org/10.1093/eurheartj/ehz753 (2019).
27. Patricio, D. Comparison of extracorporeal and conventional cardiopulmonary resuscitation: a retrospective propensity score matched study. Crit Care 23, 27, https://doi.org/10.1186/s13054-019-2230-1 (2019).
28. Lang, C. N. et al. Good long-term quality of life after emergency extracorporeal life support for cardiogenic shock and extracorporeal cardiopulmonary resuscitation. Resuscitation 143, 66–67, https://doi.org/10.1016/j.resuscitation.2019.08.003 (2019).

Acknowledgements
The authors thank Prof. Dr. Harald Langer, Luebeck, Germany for providing ideas for the project and critically discussing the manuscript. Marina Rieder was supported by the IMM-PACT-Programme for Clinician Scientists, Department of Medicine II, Medical Center – University of Freiburg and Faculty of Medicine, University of Freiburg, funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) – 413517907.
Author contributions
D.D. conceived the study, initiated and performed the analysis, wrote the manuscript, and prepared all figures and tables; V.Z. was the independent cardiologist for MI type adjudication, extracted and analyzed data and prepared Figs. 1 and 2; M.R. extracted and analyzed data; X.B. extracted and analyzed data; P.M.B. co-wrote the manuscript; K.K. performed the statistical analysis; G.T. allocated data; C.Benk allocated data; H.J.B. critically discussed study conception and edited the manuscript; C.Bode edited the manuscript; T.W. performed coronary angiography findings analysis; P.S. allocated coronary angiography data; C.V.Z.M. performed coronary angiography findings analysis; D.L.S. conceived the study, initiated and performed the analysis, and wrote the manuscript; all authors proof-read the manuscript.

Competing interests
The authors declare no competing interests.

Additional information
Correspondence and requests for materials should be addressed to D.D.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2020